Our team of experienced scientists works closely with customers to design and execute tailored strategies for nanobody discovery, ensuring the generation of high-quality leads that align with project goals.
Antibody humanization from a broad range of parental species including mouse, rat, rabbit, llama, and avian.
Our Membrane Proteomics platform offers a comprehensive solution for the identification, quantification, and characterization of membrane proteins, providing valuable insights into their functions and interactions within the cell.
Alpha Lifetech can offer the native antibody libraries (scFv, Fab, VHH Formats and customized) from host animals like Goat, Camel and Llama.
Alpha Lifetech Inc. was founded by a group of scientists with extensive experience in membrane protein production, nanobody discovery, monoclonal development, and other pharmaceutical pre-development services. Based on our several technology service platforms, Alpha Lifetech Inc. has launched nearly 10,000 high-quality spot membrane protein reagents, cytokines, drug target antibodies and other related reagents. Whether you're working in the fields of immunology, cell biology, molecular biology, or any other scientific discipline, Alpha Lifetech's comprehensive range of research products will help you achieve accurate and reliable results. We pride ourselves on being able to offer a comprehensive set of high-quality products and services tailored to customer needs, which help advance the projects of scientific research institutions, academics, and enterprises in the life science industry.
Alpacas, like other camelids, naturally produce heavy-chain-only antibodies (HCAbs). The variable domain of these antibodies — the VHH or nanobody — is the smallest known antigen-binding fragment, measuring just ~15 kDa, yet retaining full binding specificity and high affinity.
Nanobodies feature exceptional thermal and chemical stability, can access cryptic epitopes inaccessible to conventional antibodies, and maintain functionality in harsh environments — making them ideal for industrial biosensors, point-of-care diagnostics, and intracellular applications.
The alpaca immunization process typically spans 8–12 weeks, followed by library construction and phage/yeast display screening. This compressed timeline, compared to conventional mAb development, dramatically accelerates lead generation for both research and therapeutic applications.
VHH nanobodies can be readily fused to Fc domains, toxins, enzymes, or other nanobodies to create bispecific or multispecific constructs, CAR-T cell components, and advanced drug conjugates — enabling a new generation of precision therapeutics.
Nanobodies can be efficiently produced in microbial systems (E. coli, yeast) at high yields, significantly reducing manufacturing costs compared to full-length antibodies. This scalability is critical for commercial diagnostics and large-scale therapeutic production.
From oncology and infectious disease therapy to agricultural pathogen detection, food safety testing, and environmental monitoring — alpaca-derived nanobodies are reshaping multiple industries with their unparalleled versatility.
High-purity recombinant protein, peptide, or cell-based antigen preparation optimized for immunogenicity in alpacas.
Multi-round immunization protocol over 8–12 weeks with titer monitoring to confirm robust immune response.
Peripheral blood mononuclear cells are isolated from immunized alpacas for downstream VHH library construction.
RT-PCR amplification of VHH gene repertoire followed by cloning into phage or yeast display vectors with >10⁸ diversity.
Multiple rounds of bio-panning against target antigen with ELISA, SPR, and BLI-based affinity validation.
Comprehensive biophysical and functional characterization including affinity, specificity, stability, and epitope mapping.
Unlike conventional monoclonal antibody development, alpaca-derived nanobodies offer a dramatically simplified single-domain architecture that enables access to enzyme active sites, viral receptor-binding domains, and GPCR epitopes that are simply unreachable with standard IgG antibodies. Combined with superior thermostability (retaining activity up to 80°C), resistance to extreme pH, and the ability to be produced in E. coli at gram-scale — nanobodies from alpaca immunization represent the gold standard for next-generation biotherapeutic and diagnostic development.
The global single-domain antibody (nanobody) market is projected to exceed USD 4.5 billion by 2030, growing at a CAGR of over 22%. The approval of Caplacizumab (the first nanobody-based therapeutic) by the FDA and EMA has validated the clinical potential of this technology and triggered a wave of investment in alpaca immunization-based discovery programs worldwide.
Over 50 nanobody-based therapeutics are currently in clinical trials globally, targeting oncology, autoimmune diseases, neurological disorders, and infectious diseases. Bispecific nanobody constructs and nanobody-drug conjugates (NDCs) are emerging as particularly promising modalities, leveraging alpaca immunization to generate highly specific targeting moieties.
Nanobodies derived from alpaca immunization are transforming in vitro diagnostics (IVD) — from lateral flow assays and ELISA kits to cutting-edge cryo-EM chaperones and super-resolution microscopy probes. Their small size and high stability enable multiplexed diagnostic panels with unprecedented sensitivity for pathogen detection, cancer biomarkers, and environmental contaminants.
The agricultural sector is rapidly adopting alpaca nanobody technology for plant pathogen detection, veterinary diagnostics, and food safety testing. Nanobodies targeting mycotoxins, pesticide residues, and antibiotic residues in food matrices offer superior performance over conventional antibodies, with faster assay development timelines and lower production costs.
The integration of artificial intelligence and machine learning with alpaca immunization data is revolutionizing nanobody optimization. AlphaFold2-based structure prediction, combined with deep mutational scanning of VHH libraries, enables in silico affinity maturation and stability engineering — compressing development timelines from months to weeks and dramatically improving hit rates.
Nanobodies from alpaca immunization are being integrated into CAR-T and CAR-NK cell therapies as targeting domains, offering advantages over scFv-based CARs including reduced tonic signaling, improved surface expression, and the ability to target novel epitopes. Additionally, AAV-delivered nanobody gene therapies represent a frontier application for chronic disease management.
Alpha Lifetech Inc. is committed to providing the highest level of customer services, competitive pricing, speedy delivery, and a comprehensive, cutting-edge product offering. Our sales and technical support staff are available to help you select the right products and service solutions. As a reliable supplier and partner, Alpha Lifetech Inc. always puts customers first. We cherish every opportunity to collaborate with worldwide customers in scientific exploration. Welcome to contact our technical support at any time.
Alpha Lifetech Inc. provides a wide range of technology platforms, including membrane protein, antibody discovery, single B cell sorting, and hybridoma technology. Whether you're engaged in immunology, cell biology, molecular biology, or any other scientific discipline, our comprehensive suite of services is designed to empower you with precise and dependable results.
Alpaca-immunized nanobodies targeting PD-L1, EGFR, HER2, and CD19 are being developed as next-generation checkpoint inhibitors and bispecific T-cell engagers. Their small size enables superior tumor penetration compared to full IgG antibodies, while their single-domain architecture facilitates the construction of compact trispecific molecules that simultaneously engage tumor cells, T cells, and NK cells — a therapeutic strategy uniquely enabled by alpaca nanobody technology.
Furthermore, nanobody-based PET/SPECT imaging agents derived from alpaca immunization allow real-time tumor visualization with rapid blood clearance, providing oncologists with unprecedented diagnostic precision for staging and treatment monitoring.
The COVID-19 pandemic demonstrated the extraordinary speed advantage of alpaca nanobody platforms — researchers generated neutralizing VHH nanobodies against SARS-CoV-2 spike protein within weeks of sequence publication. This rapid response capability positions alpaca immunization services as a critical component of global pandemic preparedness infrastructure.
Multivalent nanobody constructs targeting conserved viral epitopes offer broad-spectrum protection against emerging variants, while inhaled nanobody formulations represent a novel prophylactic approach for respiratory pathogens — a delivery route uniquely suited to the small, stable nanobody format.
Industrial manufacturers are deploying alpaca nanobody-based biosensors for real-time quality control in pharmaceutical manufacturing, food processing, and environmental monitoring. Nanobodies immobilized on electrochemical, optical, or piezoelectric sensor platforms achieve detection limits in the picomolar range for target analytes, enabling continuous process monitoring that was previously impossible with conventional antibodies due to their instability under industrial conditions.
The thermostability of alpaca-derived nanobodies (retaining full activity after 30 minutes at 70°C) makes them uniquely suited for integration into industrial IoT sensor networks operating in harsh environments.
Alpaca nanobodies have become indispensable tools in structural biology as cryo-EM and X-ray crystallography chaperones. By binding to flexible or conformationally dynamic protein targets, nanobodies stabilize specific conformational states and increase the effective molecular weight of small protein complexes, dramatically improving cryo-EM particle alignment and resolution. This application has enabled the determination of structures for previously intractable membrane proteins including GPCRs, ion channels, and transporters — targets of immense pharmaceutical importance.
Our platform utilizes phage and yeast display technology to develop different forms of antibodies: VHH single domain antibodies, Fab antibodies, and scFv antibodies, resulting in high affinity and high specificity antibodies.
READ MORE
The aptamer platform provided by Alpha Lifetech includes two categories: aptamer synthesis platform, which mainly involves SELEX aptamer library synthesis service and aptamer development service, and aptamer screening platform including screening services based on SELEX technology for proteins, peptides, cells, small molecules, and other target molecules, as well as aptamer optimization and identification analysis services.
READ MORE
We also provide a series of technical services related to antibody engineering, stable cell line construction, yeast display, protein interaction analysis, etc., laying the foundation for antibody development.
READ MORE
Exceptional Nanobody discovery capabilities from Alpha Lifetech. Their team's dedication to customer satisfaction and scientific excellence is evident in every interaction. Grateful for their partnership and looking forward to future collaborations!
Quality products! Our experience with Alpha Lifetech has been nothing short of outstanding. The alpaca immunization service delivered exceptional nanobody hits ahead of schedule.
Reliable, responsive, and results-driven — Alpha Lifetech. Their VHH discovery pipeline is the most efficient we have worked with in over a decade of nanobody research.
Simply put, Alpha Lifetech delivers. Their dedication to customer satisfaction and quality service is unmatched, and we're grateful to have them as a trusted partner.
The alpaca immunization service from Alpha Lifetech gave us nanobodies with sub-nanomolar affinity against our GPCR target — something we had failed to achieve with conventional antibody methods over two years.
Alpha Lifetech's technical team provided outstanding support throughout our nanobody project. Their expertise in both alpaca immunization and phage display screening was invaluable to our program's success.
VHH Antibody Discovery Service for Alpaca Nanobody
Fab Antibody Discovery Service
ScFv Antibody Discovery Service
Animal Immunization Platform for Alpaca
Phage Library Construction & Screening
Single B Cell Sorting Platform
Nanobody Affinity Maturation Service
Yeast Display Library Service for Nanobody
